Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned an average recommendation of “Buy” from the ten ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $21.63.

A number of equities analysts recently weighed in on VNDA shares. Piper Jaffray Companies boosted their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, September 14th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 18th. Finally, BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd.

Several institutional investors have recently bought and sold shares of VNDA. Legal & General Group Plc raised its stake in shares of Vanda Pharmaceuticals by 37.4% during the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares during the period. Kopp Investment Advisors LLC bought a new position in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $196,000. Virginia Retirement Systems ET AL bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $193,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $196,000. Finally, Voya Investment Management LLC boosted its position in shares of Vanda Pharmaceuticals by 29.7% in the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 4,605 shares during the period. 86.49% of the stock is owned by hedge funds and other institutional investors.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 0.139% on Wednesday, reaching $17.975. 68,919 shares of the company were exchanged. The company’s 50 day moving average is $17.29 and its 200 day moving average is $15.51. The firm’s market capitalization is $806.32 million. Vanda Pharmaceuticals has a 12-month low of $12.70 and a 12-month high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The business had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. During the same quarter in the previous year, the firm earned $0.01 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. Analysts forecast that Vanda Pharmaceuticals will post ($0.42) earnings per share for the current year.

WARNING: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/vanda-pharmaceuticals-inc-vnda-receives-consensus-rating-of-buy-from-brokerages-2.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.